Which is better, ABBV or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than ABBV — 65/100 (C grade) vs 57/100 (C). That said, "better" depends on which framework you trust — ABBV wins on Benjamin Graham, Philip Fisher, and Peter Lynch; GMAB wins on Warren Buffett, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ABBV or GMAB?

This page is an educational comparison, not investment advice. Both ABBV and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ABBV better than GMAB for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 57/100, a 8-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ABBV and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ABBV currently scores 57/100 (C grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ABBV or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ABBV and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ABBV or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ABBV and GMAB both Healthcare stocks?

Yes — both AbbVie Inc. (ABBV) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ABBV vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

AbbVie

ABBV

Market cap

$384.1B

Sector

Healthcare

Overall winner

Genmab A/S

ABBV 3–4 GMAB

Genmab A/S

GMAB

Market cap

$16.47B

Sector

Healthcare

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

ABBVvsGMAB

Warren Buffett

57C

65C

Benjamin Graham

88A

64C

Philip Fisher

58C

48D

Peter Lynch

30F

25F

Joel Greenblatt

41D

76B

Charlie Munger

64D

68C

Terry Smith

56D

71C

Side-by-side metrics

Metric	ABBV	GMAB
Market cap	$384.1B	$16.47B
P/E (TTM)	103.6x	6.2x
EV/EBIT	21.8x	12.0x
ROIC (TTM)	10.29%	43.78%
Gross margin	73.46%	93.88%
Net margin	5.79%	18.23%
Revenue CAGR 5y	2.14%	-18.45%
EPS CAGR 5y	-22.23%	-23.48%
Debt / Equity	2.6x	0.1x
Dividend yield	3.17%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ABBV leads on

Revenue CAGR 5y2.14%vs -18.45%+112%
Dividend yield3.17%vs 0.0%+100%
Market cap$384.1Bvs $16.47B+96%
EPS CAGR 5y-22.23%vs -23.48%+5%

GMAB leads on

Debt / Equity0.1xvs 2.6x+97%
P/E (TTM)6.2xvs 103.6x+94%
ROIC (TTM)43.78%vs 10.29%+76%
Net margin18.23%vs 5.79%+68%

More like ABBV

ABBV vs HALO ABBV vs LMAT ABBV vs 7741.T ABBV vs LLY ABBV vs RMD ABBV vs UTHR

More like GMAB

GMAB vs HALO GMAB vs LMAT GMAB vs 7741.T GMAB vs LLY GMAB vs RMD GMAB vs UTHR

Read the full Buffett-Brain analysis for ABBV Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

AbbVie

ABBV

Market cap

$384.1B

Sector

Healthcare

Overall winner

Genmab A/S

ABBV 3–4 GMAB

Genmab A/S

GMAB

Market cap

$16.47B

Sector

Healthcare

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

ABBVvsGMAB

Warren Buffett

57C

65C

Benjamin Graham

88A

64C

Philip Fisher

58C

48D

Peter Lynch

30F

25F

Joel Greenblatt

41D

76B

Charlie Munger

64D

68C

Terry Smith

56D

71C

Side-by-side metrics

Metric	ABBV	GMAB
Market cap	$384.1B	$16.47B
P/E (TTM)	103.6x	6.2x
EV/EBIT	21.8x	12.0x
ROIC (TTM)	10.29%	43.78%
Gross margin	73.46%	93.88%
Net margin	5.79%	18.23%
Revenue CAGR 5y	2.14%	-18.45%
EPS CAGR 5y	-22.23%	-23.48%
Debt / Equity	2.6x	0.1x
Dividend yield	3.17%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ABBV leads on

Revenue CAGR 5y2.14%vs -18.45%+112%
Dividend yield3.17%vs 0.0%+100%
Market cap$384.1Bvs $16.47B+96%
EPS CAGR 5y-22.23%vs -23.48%+5%

GMAB leads on

Debt / Equity0.1xvs 2.6x+97%
P/E (TTM)6.2xvs 103.6x+94%
ROIC (TTM)43.78%vs 10.29%+76%
Net margin18.23%vs 5.79%+68%

More like ABBV

ABBV vs HALO ABBV vs LMAT ABBV vs 7741.T ABBV vs LLY ABBV vs RMD ABBV vs UTHR

More like GMAB

GMAB vs HALO GMAB vs LMAT GMAB vs 7741.T GMAB vs LLY GMAB vs RMD GMAB vs UTHR

Read the full Buffett-Brain analysis for ABBV Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.